Publications by authors named "D Flex"
Article Synopsis
- The study examined the effectiveness of topical treatments for managing the rash caused by epidermal growth factor receptor inhibitors (EGFRIs) in cancer patients, which occurs in 60-85% of cases.
- In a randomized trial, patients received either a combination ointment (chloramphenicol and prednisolone), chloramphenicol alone, or aqua cream to see how they influenced rash severity.
- Results showed that the combination ointment significantly reduced the incidence of a specific type of significant rash compared to the aqua cream, suggesting it is a better prophylactic treatment.
The original article [1] contained an error whereby all authors' names were mistakenly inverted. This error has now been corrected.
View Article and Find Full Text PDFIntroduction: Advanced non-small cell lung cancer (NSCLC) is still a therapeutic challenge as the 5-year survival is under 30%. The optimal treatment regimen is still under debate.
Hypothesis: Neo adjuvant (NA) treatment given pre-pneumonectomy does not increase surgical complexity or peri-OP mortality while it has a potential to increase long term survival.
Background: Trimodality therapy (chemoradiation followed by surgery) provides a benefit in progression-free survival but not overall survival. We sought to determine if a high dose of radiation could be delivered safely and provide a clinical benefit.
Methods: Consecutive patients with stage IIIA or IIIB non-small-cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy followed by surgery were reviewed with IRB approval.
Objectives: Nivolumab has recently received regulatory approval as a 2nd-line treatment of non-small cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real life setting is lacking.
Materials And Methods: 260 consecutive patients with advanced NSCLC treated with nivolumab at five Israeli cancer centers between January 2015 and March 2016 were evaluated for overall survival (OS) and toxicity.